1 Inpatient treatment for severe obesity: a retrospective

2	cohort	study	<i>ı</i> in Brazil
---	--------	-------	--------------------

4	Domingos L.	S.	Rios ′	1, 2.;	Márcia	C.	A.	M.	Oliveira	1, 2	; Sérgio Q	. Braga1;	Matheus	J

Chamorro 2; Beatriz L. B. Cunha 2; Ana C. R. Reis 2; Ana P. Guimarães2; Ana D. N. Silva

2; Dandara A. R. Silva 1, 2; Edilene M. Q. Araújo 2; Magno M. W. Pimentel 2

¹Hospital da Obesidade, Camaçari, Bahia, Brazil.

Short title: Inpatient treatment for severe obesity

- ⁹ ²Departamento de Ciências da Vida DCV, Universidade do Estado da Bahia, Salvador,
- 10 Bahia, Brazil.

3

5

7

11

13

14

15

16

17

18

19

12 E-mail of the corresponding author: drios@uneb.br

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

Introduction: Very low-calorie diets with hospitalization have demonstrated promise as a viable therapeutic option for severe obesity and its associated comorbidities. However, large studies providing a comprehensive longitudinal observation of patients undergoing this therapy are lacking. We evaluated the effectiveness of treating severe obesity in hospitalized patients, using very low-calorie diets and clinical support to develop lifestyle changes. **Methods**: A retrospective cohort study with a pre-post quasi-experimental design analyzed secondary data from 2016–2022 medical records of patients with severe obesity (grade II or III) treated in a Brazilian obesity specialist hospital. The patients underwent a very lowcalorie diet (500-800 kCal/day) and immersive changes in lifestyle habits, monitored by a multidisciplinary team. At 3 months, 777 patients presented complete data and 402 presented complete data at 6 months. The study compared changes in bioimpedance and laboratory tests, between men and women and age groups (elderly vs. non-elderly). **Results**: Three months of hospitalization yielded significant reductions in weight, body mass index (BMI), body fat, skeletal muscle mass, glucose, inflammatory, and lipid parameters. These reductions were more pronounced after 6 months, nearly doubling those observed at 3 months. In women, BMI and fat mass reduced by 10.4% and 15.2% at 3 months and 20.4% and 31.3% at 6 months, respectively. In men, BMI and fat mass decreased by 12.9% and 25.3 at 3 months and 23.6% and 45.3% at 6 months, respectively. Elderly individuals (aged ≥ 60 years) had smaller reductions in BMI and fat mass than non-elderly individuals (aged < 60 years) but still presented significant improvements.

Conclusion: This study suggests the viability of treating severe obesity by hospitalization with low-calorie diets and immersive lifestyle changes. This treatment modality significantly improves anthropometric measurements, glucose, lipids, and inflammatory markers, thereby reducing cardiovascular risk. **Keywords:** severe obesity; inpatient treatment; very low-calorie diet

Introduction

61

81

82

Obesity is a clinical condition characterized by increased body weight resulting from 62 excessive fat accumulation, influenced by genetic, biological, environmental, and 63 sociocultural factors [1]. 64 Considered a public health problem, obesity is associated with the development of several 65 chronic non-communicable diseases, including metabolic syndrome, dyslipidemia, insulin 66 resistance, cardiovascular diseases, type 2 diabetes mellitus, osteoarthritis, sleep apnea, 67 infertility, cancer, and psychological problems [2-3]. The global prevalence of obesity has 68 increased, partly due to changes in eating patterns, with increased consumption of calorie-69 rich foods and unhealthy lifestyle habits, such as sedentarism. 70 Very low-calorie diets (VLCDs) have been proposed as a valid treatment option for grade II 71 72 and III obesity, with or without comorbidities [4]. This diet involves altering and optimizing energy metabolism, stimulating the production of ketone bodies by the liver through the 73 breakdown of fat, inducing weight loss, and improving other parameters such as insulin 74 sensitivity and glycemic control [5-6]. 75 Owing to the multiple interactions of causal factors, treating obesity requires an 76 interdisciplinary and integrated therapeutic approach focused on lifestyle changes. In this 77 scenario, hospitalization emerges as an interesting therapeutic strategy, offering a 78 79 multidisciplinary intervention that successfully achieves weight loss [7]. This study aimed to evaluate the effectiveness of treating severe obesity (grades II and III) 80

in hospitalized patients, using VLCD and clinical support to develop lifestyle changes.

Materials and Methods

Type of study- sample design

This retrospective cohort study was conducted using secondary data from the medical records of patients hospitalized in a controlled environment for weight loss from October 2016 to October 2022. It employed a quasi-experimental design with an interventional before-after (pre-post) design.

The research was conducted at a Brazilian hospital specialized in obesity treatment. The sample size was convenience-based, initially comprising 1,151 individuals with severe obesity hospitalized for 3 and/or 6 months. The inclusion criteria were age over 12 years, obesity grade II or III upon admission, and at least 3 months of inpatient treatment. We excluded 293 patients without data from laboratory tests and/or bioimpedance. We included 858 patients in the analysis. Of these, 321 presented complete data at 3 and 6 months, 456 presented complete data at 3 months alone, and 81 presented complete data

at 6 months alone. Therefore, the analysis included 777 patients with data available at 3

months and 402 with data available at 6 months. Data was imported directly from the

electronic medical records of each patient into an Excel table and then converted directly

into SPSS format using SPSS software ver. 29.0.1.0 (IBM corporation, New York, USA) for

statistical analysis. Data was assessed from electronic medical records from July 31, 2023

for research purposes. The authors had no access to information that could identify

individual participants during and after data collection.

Therapeutic interventions and multi-professional support

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

The treatment involved a multidisciplinary approach with key components including lowcalorie diets (LCDs) and VLCDs, physical activity, individual cognitive behavioral therapy (CBT), participation in educational groups aimed at lifestyle changes, and multidisciplinary clinical support. Patients received LCDs (800 to 1,200 kCal/day) or VLCDs (less than 800 kCal/day) during hospitalization. Both diets provided a higher percentage of protein (70 to 100 g/day or 0.8 to 1.5 g /kg of ideal body weight/day) and a low carbohydrate content. These diets were supplemented with vitamins, minerals, electrolytes, and essential fatty acids to ensure adequate nutrition, following Brazilian guidelines for treating obesity [8]. Patients engaged in lower-impact physical activities due to frequent arthropathies, including water aerobics exercises at least thrice a week, horizontal biking twice a week with a light load, and weight training thrice a week. The patients underwent individual one-hour CBT sessions with a psychologist twice weekly. Patients also participated in educational group activities. methodologies and experiences aimed at lifestyle changes, consisting of daily one-hour meetings [9-10]. Daily clinical evaluations were conducted, with periodic consultations by endocrinologists, cardiologists, orthopedists, and psychiatrists. A team of physiotherapists, occupational therapists, and nurses assessed and monitored each patient's condition, providing necessary interventions in their respective areas.

Bioimpedance and anthropometry

All patients had their weight and height measured and underwent bioimpedance testing upon admission and at 3 and/or 6 months. Height was measured using a stadiometer (Tonelli Medical Devices, Brazil), and weight was measured using a bioelectrical impedance device. Body composition was assessed using a 3-frequency bioelectrical impedance device (5kHz, 50kHz, and 5,00kHz–Ottoboni-inbody570), utilizing a tetra polar system with eight points (tactile electrodes) to obtain 15 impedance measurements of each of the five body segments (right arm, left arm, trunk, right leg, and left leg). Obesity severity was assessed using body mass index (BMI): grade I, if BMI was between 30 and 34.9 kg/m²; grade II, between 35 and 39.9 kg/m²; and grade III, ≥40 kg/m².

Laboratory tests

Measurements of gamma-glutamyl transferase (GGT), blood glucose, triglycerides, total cholesterol, and high-density cholesterol (HDL) were performed using the enzymatic colorimetric method; low-density cholesterol (LDL) was calculated using the Friedewald formula. Serum zinc levels were measured using the flame atomic absorption spectrometry method. Electrochemiluminescence was used to measure ferritin and basal insulin levels. Oxaloacetic (GOT) and pyruvic (GPT) transaminases were measured using the UV-kinetic method; creatine phosphokinase (CPK) by the UV method; glycated hemoglobin HbA1c by turbidimetric inhibition immunoassay; C-reactive protein (CRP) by immunoturbidimetry. All tests were performed using an automated device and in the same laboratory.

Statistical analysis

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

The bioimpedance parameters were described as median and inter-quartil interval. To compare values measured at admission with those observed after 3 and 6 months of hospitalization it was used the Wilcoxon test. The percentage change in each bioimpedance parameter was calculated by subtracting the values measured at admission from those obtained at 3 and 6 months of hospitalization, respectively. This difference was divided by the original hospitalization value and multiplied by 100. These percentage values were compared between men and women and between elderly (≥60 years) and non-elderly patients (<60 years) using a Mann-Whitney test. Laboratory measurements on admission and at 3 and 6 months of hospitalization were compared using a Wilcoxon test. Kaplan-Meier curves were used to compare the time to reach 20% weight loss and 35% fat mass reduction between male and female and between elderly and no elderly patients. To evaluate the factors associated with the success to reach median values of fat mass loss at 3 and 6 months of hospitalization, a multivariate logistic regression was performed: the dependent variables were the success of reach the median percentage of fat mass loss in each period of hospitalization (17% and 35% at 3 and 6 months hospitalization, respectively). The independent variables were included in the model, using the "forward conditional" method, the initial following dummy variables were used in the analysis: age ≥ 60 years, male sex, Diabetes Mellitus, current smoking, drinking habits, hypothyroidism, hepatic steatosis, sedentary life style and altered admission levels of glycated hemoglobin (> 5.6%), zinc $(< 69.93 \mu g/dL)$, CRP (> 6 m g/L), and CPK (> 200 U/L). A significance level of 5% was adopted.

Ethical aspects

This research was conducted following the principles of bioethics in accordance with resolution 466/2012 (CONEP/Brazil) and met aspects related to the Declaration of Helsinki. The Research Ethics Committee of the State University of Bahia (UNEB) approved the project with CAAE number 65578822.1.0000.0057. Informed consent paperwork could not be obtained due to the retrospective design of this analysis; patients were no longer available to sign informed consent. The Research Ethics Committee approved this.

Results

Table 1 presents the clinical and epidemiological data. Women were the majority (70%) with a median age of approximately 44 years, not differing significantly between the groups by length of hospitalization. Regarding lifestyle habits, smoking (3 months: 22.1% vs. 6 months: 23.4%), drinking habits (3 months: 50.6% vs. 6 months: 49.3%) and sedentary lifestyle (3 months: 82.5% vs. 6 months: 85.6%) were prevalent and similar between the two groups.

Table 1. Clinical and epidemiological characteristics

Variable	Three months tratment	Six months treatment	p*	
	(n=777)	(n=402)		
Female sex	70.3% (546)	70.6% (284)	0.947	
Age (years)	44 (33-59)	46 (34-61,2)	0.102**	
Current smoking	22.1% (172)	23.4% (94)	0.680	
Drinking habits	50.6% (393)	49.3% (198)	0.711	
Sedentary lifestyle	82.5% (641)	85.6% (344)	0.205	
Diabetes Mellitus	34.6% (269)	32.6% (131)	0.526	
lypertension	53% (412)	52% (209)	0.783	
ypercholesteroleamia	44.3% (344)	42.8% (172)	0.670	
lypertriglyceridemia	30.9% (240)	31.1% (125)	0.995	
ypothyreiodism	15.3% (119)	17.4% (70)	0.397	
oronary Artery Disease	16% (124)	17.4% (70)	0.579	
leep apnea	75.3% (585)	78.1% (314)	0.314	
lepatic steatosis	75.8% (589)	74.4% (299)	0.640	
Depression ***	30.8% (239)	33.1% (133)	0.454	
Obesity grade II	37.1% (288)	24.1% (97)	<0.001	
Obesity grade III	62.9% (489)	75.9% (305)	< 0.001	

The prevalence of diabetes mellitus (3 months: 32.6% vs. 6 months: 34.6%), hypertension (3 months: 52% vs. 6 months: 53%), hypercholesterolemia (3 months: 42.8% vs. 6 months: 44.3%) and hypertriglyceridemia (3 months: 31.1% vs. 6 months: 30.9%) was high and did not differ significantly between groups by length of hospitalization. Hepatic steatosis (3 months: 74.4% and 6 months: 75.8%), sleep apnea (3 months: 78.1% and 6 months: 75.3%) and depression (3 months: 33.1% and 6 months: 30.8%) were prevalent in both periods of hospitalization. Patients with 6 months of hospitalization had a higher

^{192 *} Pearson chi-square with Yates' correction;

^{193 **} MannWhitney test, data is presented as median and interquartile interval values;

^{194 ***} Self-referred.

percentage of most severe obesity (grade III: 75.9%) than patients who remained hospitalized for 3 months (62.9%) (Table 1).

Table 2. Changes in bioimpedance based on length of hospitalization

Paramethers	Admission n = 777	Three months n = 777	p*	Admission n = 402	Six months n = 402	•p*
Wheight (kg)	112.7 (100.9-126.3)	100.2 (89.7-111.7)	<0.001	116.4 (103.7-130.2)	91.6 (83.8-101.9)	<0.001
BMI (kg/m²)	40.9 (39.1-44.5)	36.4 (34.7-39.4)	<0.001	42.6 (40.0-46.1)	33.4 (31.5-36.4)	<0.001
Fat mass (kg)	55.7 (50.4-63.9)	45.8 (40.6-52.3)	<0.001	58.9 (52.9-67.2)	38.0 (32.9-44.9)	<0.001
Body fat percentage(%)	51.3 (48.6-53.3)	47.8 (43.0-51.3)	<0.001	52.0 (50.0-53.7)	43.2(37.6-48.0)	<0.001
Skeletal muscle mass (kg)	31.3 (27.3-36.9)	28.9 (24.8-34.4)	<0.001	30.6 (27.1-36.3)	29.0 (25.4-34.6)	<0.001
Basal metabolic rate (kCal)	1568.0 (1436.8-1775.5)	1498.5 (1354.5-1698.8)	<0.001	1549.0 (1423.5-1760.0)	1497.0 (1368.0-1697.5)	<0.001
Waist to hip ratio	1.07 (1.00-1.14)	1.00 (0.95-1.05)	<0.001	1.08 (1.02-1.13)	1.03 (0.98-1.08)	<0.001
	•	•	•	•	•	•
	•	•	•	•	•	•

*Wilcoxon test, data is presented as median and interquartile interval values.

After 3 months of hospitalization, body weight reduced from 112.7kg to 100.2kg, BMI from 40.9 kg/m² to 36.4 kg/m², fat mass from 55.7kg to 45.8kg, fat percentage from 51.3% to 47.8%, skeletal muscle mass from 31.3kg to 28.9kg, basal metabolic rate from 1,568 kCal to 1,498 kCal, and waist-to-hip ratio (WHR) from 1.07 to 1.00 (Table 2).

Patients hospitalized for 6 months demonstrated an even greater reduction in all analyzed bioimpedance parameters. Body weight reduced from 116.4kg to 91.6kg, BMI from 42.6kg/m² to 33.4kg/m²; fat mass from 58.9kg to 38kg, fat percentage from 52% to 43.2%, skeletal muscle mass from 30.6kg to 29kg, basal metabolic rate from 1,549 kCal to 1,497 kCal, and WHR from 1.08 to 1.03 (Table 2).

After 3 months of hospitalization, men exhibited a higher percentage of reduction than women in the following bioimpedance parameters: weight (men: 12.9% vs. women: 10.4%), BMI (men: 12.9% vs. women: 10.4%), fat mass (men: 25.3% vs. women: 15.2%), body fat percentage (men: 13.6% vs. women: 5.2%), and WHR (men: 6.5% vs. women: 3.3%). However, for basal metabolic rate (men: 2.5% vs. women: 3.8%) and skeletal muscle mass (men: 3.8% vs. women: 5.9%), men exhibited a lower reduction than women (Table 3).

Table 3. Changes in bioimpedance by sex

	Three months	•	•		Six months	·
Paramethers	Famale n = 546	Male n = 231	P*	Female n = 284	Male n = 118	P*
Wheight lost percentual (%)	10.4 (8.9-12.0)	12.9 (11.1-14.7)	<0.001	20.4 (17.4-23.4)	23.6 (20.9-27.4)	<0.001
BMI lost percentual (%)	10.4 (8.9-12.0)	12.9 (11.1-14.7)	<0.001	20.4 (17.4-23.4)	23.6 (20.9-27.4)	<0.001
Fat mass lost percentual (%)	15.2 (12.3-18.5)	25.3 (19.6-30.0)	<0.001	31.3 (26.0-37.8)	45.3 (36.0-51.6)	<0.001
Reduction in body fat percentual (%)	5.2 (3.0-8.6)	13.6 (8.7-18.3)	<0.001	14.3 (8.4-20.5)	27.3 (17.7-35.3)	<0.001
Skeletal muscle mass lost percentual (%)	5.9 (7.3-8.3)	3.8 (1.4 - 6.4)	<0.001	8.7 (5.4-12.8)	6.6 (2.3-10.2)	<0.001
Basal metabolic rate reduction percentual (%)	3.8 (1.9-5.5)	2.5 (0.7 - 4.3)	<0.001	5.5 (2.9-8.5)	4.3 (1.4-7.0)	0.002
Waste to rip ratio reduction percentual (%)	3.3 (0-6.2)	6.5 (3.2 - 9.6)	<0.001	6.2 (1.2-9.5)	10.0 (3.8-16.6)	<0.001

^{*} MannWhitney test, data is presented as median and interquartile interval values.

Fig 1. Weight loss survival curve by sex during inpatient treatment. 231 Medians to reach 20% of weight loss: Female 5 months (95%CI: 4.8-5.2 months); Male 4 232 months (95%CI: 3.8-4.2 months); Log rank (Mantel-Cox test): 73.03; p<0.001. 233 234 Fig 2. Fat mass loss survival curve by sex during inpatient treatment. 235 Medians to reach 35% of fat mass loss: Female 6 months (95%CI: 5.8-6.2 months); Male 236 4 months (95%CI: 3.8-4.2 months); Log rank (Mantel-Cox test): 236.885; p<0.001. 237 238 Similarly, but to a greater extent, at 6 months of hospitalization, men exhibited higher 239 240 percentages of loss in weight (men: 23.6% vs. women: 20.4%), BMI (men: 23.6% vs. women: 20.4%), fat mass (men: 45.3% vs. women: 31.3%), body fat percentage (men: 241 27.3% vs. women: 14.3%), and WHR (men: 10% vs. women: 6.2%). Conversely, women 242 had higher rates of loss of skeletal muscle mass (men: 6.6% vs. women 8.7%) and basal 243 metabolic rate (men: 4.3% vs. women: 5.5%) (Table 3). 244 The Survival Kaplan-Meier curves compares male and female for the time to reach 245 reductions of 20% weight (Figure 1) and 35% fat mass (Figure 2) in the period of 246 247 treatment. The females reach 20% weight reduction by the fifth month while males reach this by the fourth month of treatment (p<0.001). The females reach 35% fat mass 248 reductions by the sixth month while males reach this in the fourth month of treatment 249 (p<0.001). 250 After 3 months of hospitalization, the elderly (≥ 60 years) demonstrated a lower 251

percentage of loss in weight (elderly: 10.2% vs. non-elderly: 11.4%), BMI (elderly: 10.3%

vs. non-elderly: 11, 4%), fat mass (elderly: 14.5% vs. non-elderly: 17.6%), body fat percentage (elderly: 4.9% vs. non-elderly: 7.3%), and WHR (elderly: 3.6% vs. non-elderly: 4.4%) than the non-elderly. The percentage differences in skeletal muscle mass loss 255 (elderly: 5.9% vs. non-elderly: 5.2%) but not in the basal metabolic rate (elderly: 3.8% vs. 256 non-elderly: 3.3%) was higher in elderly as compared to no elderly patients (Table 4). 257 Similarly, after 6 months of hospitalization, the elderly had a lower percentage of loss in 258 weight (elderly: 19.8% vs. non-elderly: 21.8%), BMI (elderly: 19.8% vs. non-elderly: 21.8%), fat mass (elderly: 30.5% vs. non-elderly: 37.0%), body fat percentage (elderly: 12.9% vs. non-elderly: 18.9%) and WHR (elderly: 4.4% vs. non-elderly: 7.6%). Contrary to 261 the observation after 3 months, elderly individuals had a higher percentage of loss of 262 skeletal muscle mass (elderly: 10.2% vs. non-elderly: 7.2%) and basal metabolic rate 263 264 (elderly: 6.3 % vs. non-elderly: 4.6%) at 6 months of hospitalization (Table 4).

Table 4. Changes in bioimpedance by age

253

254

259

260

265

266

	Three months			Six months			
Paramethers	Non-elderly	Elderly	p*	Non-elderly	Elderly	***	
Paramethers	n = 598	n = 179	P.	n = 290	n = 112	p*	
Wheight lost percentual (%)	11.4 (9.6-13.0)	10.2 (8.4-12.1)	<0.001	21.8 (18.8-25.4)	19.8 (17.0-22.7)	<0.001	
BMI lost percentual (%)	11.4 (9.6-13.0)	10.2 (8.4-12.1)	<0.001	21.8 (18.8-25.4)	19.8 (17.0-22.7)	<0.001	
Fat mass lost percentual (%)	17.6 (13.8-23.5)	14.5 (11.4-19.5)	<0.001	37.0 (29.4-45.4)	30.5 (24.9-35.9)	<0.001	
Reduction in body fat percentual (%)	7.3 (4.1-12.4)	4.9 (2.8-9.7)	<0.001	18.9 (11.9-27.1)	12.9 (8.0-17.2)	<0.001	
Skeletal muscle mass lost percentual (%)	5.2 (2.3-7.7)	5.9 (3.7-8.1)	0.026	7.2 (3.9-11.8)	10.2 (6.6-12.8)	<0.001	
Basal metabolic rate reduction percentual (%)	3.3 (1.3-5.2)	3.8 (2.0 - 5.3)	0.124	4.6 (2.3-8.0)	6.3 (3.9-8.2)	<0.001	
Waste to rip ratio reduction percentual (%)	4.4 (1.1-7.3)	3.6 (-1.0 - 6.7)	0.006	7.6 (3.0-12.3)	4.4 (-2.0 - 8.7)	<0.001	

^{*} Mann-Whitney test, data is presented as median and interguartile interval values.

Fig 3. Weight loss survival curve by age during inpatient treatment. 269 Medians to reach 20% of weight loss: Non-elderly patients 5 months (95%CI: 4.8-5.2 270 months); Elderly patients 6 months (95%CI: 5.8-6.2 months); Log rank (Mantel-Cox test): 271 272 29.47; p<0.001. 273 Fig 4. Fat mass loss survival curve by age during inpatient treatment. 274 Medians to reach 35% of fat mass loss: Non-elderly patients 5 months (95%CI: 4.8-5.2 275 months); Elderly patients 6 months (95%CI: 5.8-6.2 months); Log rank (Mantel-Cox test): 276 29.465; p<0.001. 277 278 Three months of hospitalization yielded a significant reduction in the levels of fasting 279 glucose (admission: 93.0 mg/dL vs. 3 months: 88.0 mg/dL), insulin (admission: 22.2 280 μIU/mL vs. 3 months: 16.8 μIU/mL) and glycated hemoglobin (admission: 5.6% vs. 3 281 months: 5.3%); triglycerides (admission: 119.0 mg/dL vs. 3 months: 94.0 mg/dL), HDL 282 (admission: 45 mg/dL vs. 3 months: 43 mg/dL), LDL (admission: 114 mg/dL vs. 3 months: 283 90 mg/dL), and total cholesterol (admission: 185 mg/dL vs. 3 months: 153 mg/dL). 284 Regarding liver injury and inflammatory markers, CRP (admission: 8.2 mg/L vs. 3 months: 285 5.2 mg/dL), ferritin (admission: 165 ng/mL vs. 3 months: 137 ng/mL), and GGT (admission: 286 35 mg/dL vs. 3 months: 25 mg/dL) levels significantly reduced after 3 months of treatment. 287 However, GPT increased slightly (admission: 24.5 mg/dL vs. 3 months: 27.2 mg/dL) while 288 GOT remained unchanged during this period of hospitalization (Table 5). 289

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

Similarly, but to a greater extent, after 6 months of hospitalization, almost all parameters evaluated reduced significantly, including fasting glucose (admission: 93.5 mg/dL vs. 6 months: 87.0 mg/dL); insulin (admission: 22.1 µIU/mL vs. 6 months: 13.7 µIU/mL); glycated hemoglobin (admission: 5.6% vs. 6 months: 5.3%); triglycerides (admission: 119 mg/dL vs. 6 months: 85 mg/dL); LDL (admission: 115 mg/dL vs. 6 months: 98 mg/dL), and total cholesterol (admission: 186 mg/dL vs. 6 months: 164 mg/dL). However, HDL levels remained unchanged (admission: 46 mg/dL vs. 6 months: 45.5 mg/dL). Regarding liver injury and inflammatory parameters, a significant reduction was observed in the values of GGT (admission: 37 mg/dL vs. 6 months: 24 mg/dL), GPT (admission: 23.1 mg/dL vs. 6 months: 22.7 mg/dL), CRP (admission: 8 mg/L vs. 6 months: 6.5 mg/L), and ferritin (admission: 165 ng/mL vs. 6 months: 139 ng/mL). Contrary to the observation at 3 months, GOT levels increased within the normal range (admission: 22.7 mg/dL vs. 6 months: 21.9 mg/dL) (Table 5). The Survival Kaplan-Meier curves compares non-elderly and elderly patients for the time to reach reductions of 20% in weight (Figure 3) and 35% in fat mass (Figure 4) during treatment. Elderly patients reach 20% weight (p<0.001) and 35% fat mass (p<0.001) reductions by the sixth month of treatment as compared to 5 months for non-elderly patients.

Table 5. Changes* in glycide, lipid, and hepatic parameters

	Admission	Three months		Admission	Six months	
Paramethers	n=777	n=777		n=402	n=40 2	– p ––––––
Fasting glucose (mg/dL)	93.0 (85.0-106.0)	88.0 (82.0-95.0)	<0.001	93.5 (85.0-107.0)	87.0 (81.0-93.2)	<0.001
Insulin (µUI/mL)	22.2 (15.5-31.7)	16.8 (11.3-23.2)	<0.001	22.1 (15.6-32.6)	13.7 (9.2-18.6)	<0.001
Glycated haemoglobin (%)	5.6 (5.3-6.0)	5.3 (5.0-5.7)	<0.001	5.6 (5.3-6.0)	5.3 (5.0-5.6)	<0.001
Triglycerides (mg/dL)	119.0 (91.0-161.0)	94.0 (77.0-119.0)	<0.001	119.0 (93.0-156.0)	85.0 (70.0-106.0)	<0.001
HDL (mg/dL)	45.0 (38.0-53.0)	43.0 (37.0-50.0)	<0.001	46.0 (39.0-55.0)	45.5 (40.0-54.0)	0.865
LDL (mg/dL)	114.0 (91.0-139.0)	90.0 (68.0-111.0)	<0.001	115.0 (93.0-138.2)	98.0 (76.8-117.2)	<0.001
Total Cholesterol (mg/dL)	185.0 (159.0- 215.0)	153.0 (130.0-177.0)	<0.001	186.0 (162.8- 216.2)	164.0 (142.0-186.2)	<0.001
C reactive protein (mg/L)	8.2 (4.2-13.8)	5.2 (2.6-10.5)	<0.001	8.0 (4.5-13.7)	6.5 (3.0-8.7)	<0.001
Ferritin (ng/mL)	165.0 (82.5-286.0)	137.0 (67.5-259.0)	<0.001	165.0 (80.8-285.2)	139.0 (68.0-257.0)	0.001
GOT (mg/dL)	22.3 (18.0-29.9)	23.1 (18.7-30.2)	0.282	22.7 (18.0-30.0)	21.9 (17.7-29.7)	0.431
GPT (mg/dL)	24.5 (17.3-37.0)	27.2 (18.7-40.6)	0.001	23.1 (17.1-37.2)	22.7 (16.3-34.6)	0.009
GGT (mg/dL)	35.0 (23.5-56.0)	25.0 (17.0-41.0)	<0.001	37.0 (24.0-59.0)	24.0 (17.0-44.0)	<0.001

^{*}Wilcoxon test, data is presented as median and interquartile interval values.

Table 6 presents the multivariate logistic regression with the factors, measured at admission, associated with the success to reach the median percentage of fat mass loss during hospitalization. After three months, male sex, drinking habits, CPK above normal range (>200 U/L) were associated with a higher odds ratio to reach the median percentage of body fat mass loss (17%). An inverse association was observed with elderly (age \geq 60 years), C-reactive protein level above the normal range (> 6mg/dl), and zinc level below the normal range (< 69,93 µg/dL) [Table 6].

At six months of hospitalization, some of these predictors lost significance, with male sex, hepatic steatosis, and elderly remaining significant. Similar to the results at 3 months, elderly people presented a lower odds ratio to reach the median percentage of body fat mass loss at 6 months (34%), while males presented higher odds ratio to reach such loss. Alcohol consumption and glycated hemoglobin levels, testosterone, zinc, and magnesium were no longer significant predictors of body fat mass loss at 6 months (Table 6).

Table 6. Factor associated with body fat mass loss* in both periods of inpatient treatment.

Constant 0.809 0.256 0.484 0.004 Male sex 7.51 4.96-11.38 <0.001 7.36 4.29-12.64 <0.001 Elderly (age ≥ 60 years) 0.34 0.22-0.52 <0.001 0.28 0.17-0.47 <0.001 Drink habit 1.50 1.08-2.09 0.016 Hepatic steatosis 1.92 1.12-3.30 0.018 Creactive protein > 6mg/L 0.52 0.36-0.75 0.001 Creatine phosphokinase > 200 U/L 2.21 1.50-3.26 <0.001		Three month	s R2 = 0.335		Six months	R2 = 0.287	
Constant 0.809 0.256 0.484 0.004 Male sex 7.51 4.96-11.38 <0.001 7.36 4.29-12.64 <0.001 Elderly (age ≥ 60 years) 0.34 0.22-0.52 <0.001 0.28 0.17-0.47 <0.001 Drink habit 1.50 1.08-2.09 0.016 Hepatic steatosis 1.92 1.12-3.30 0.018 Creactive protein > 6mg/L 0.52 0.36-0.75 0.001 Creatine phosphokinase > 200 U/L 2.21 1.50-3.26 <0.001		n=777			n=402		
Male sex 7.51 4.96-11.38 <0.001 7.36 4.29-12.64 <0.001 Elderly (age ≥ 60 years) 0.34 0.22-0.52 <0.001 0.28 0.17-0.47 <0.001 Drink habit 1.50 1.08-2.09 0.016 1.92 1.12-3.30 0.018 C reactive protein > 6mg/L 0.52 0.36-0.75 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001	Variables	Odss ratio	95% CI	р	Odss ratio	95% CI	р
Elderly (age ≥ 60 years) 0.34 0.22-0.52 <0.001	Constant	0.809		0.256	0.484		0.004
Drink habit 1.50 1.08-2.09 0.016 1.92 1.12-3.30 0.018 C reactive protein > 6mg/L 0.52 0.36-0.75 0.001 1.2-3.30 0.018 Creatine phosphokinase > 200 U/L 2.21 1.50-3.26 <0.001	Male sex	7.51	4.96-11.38	<0.001	7.36	4.29-12.64	<0.001
Hepatic steatosis 1.92 1.12-3.30 0.018 C reactive protein > 6mg/L 0.52 0.36-0.75 0.001 Creatine phosphokinase > 200 U/L 2.21 1.50-3.26 < 0.001	Elderly (age ≥ 60 years)	0.34	0.22-0.52	<0.001	0.28	0.17-0.47	<0.001
C reactive protein > 6mg/L 0.52 0.36-0.75 0.001 Creatine phosphokinase > 200 U/L 2.21 1.50-3.26 <0.001	Drink habit	1.50	1.08-2.09	0.016			
Creatine phosphokinase > 200 U/L 2.21 1.50-3.26 < 0.001	Hepatic steatosis				1.92	1.12-3.30	0.018
	C reactive protein > 6mg/L	0.52	0.36-0.75	0.001			
Zinc < 69.93μg/dL 0.51 0.29-0.89 0.018	Creatine phosphokinase > 200 U/L	2.21	1.50-3.26	<0.001			
	Zinc < 69.93µg/dL	0.51	0.29-0.89	0.018			

*Multiple Logistic Regression. The independent variable was the success to reach the median value for fat mass reduction percentage (17% by the third month and 35% by the sixth month). The independent variables were included in the model, using the "forward conditional" method, the initial following dummy variables were used in the analysis: age \geq 60 years, male sex, Diabetes Mellitus, current smoking, drinking habits, hypothyroidism, hepatic steatosis, sedentary life style and altered admission levels of glycated hemoglobin (> 5.6%), zinc (< 69.93 µg/dL), CRP (> 6 mg/L), and CPK (> 200 U/L). 95% CI: 95% Confidence Interval.

Discussion

Most hospitalized patients were women, presented with drinking habits, and had a sedentary lifestyle. The most prevalent comorbidities were hypertension, diabetes, hypercholesterolemia, hypertriglyceridemia, hypothyroidism, coronary artery disease, sleep apnea, hepatic steatosis, and self-reported depression. These data did not differ between the 3 and 6-month hospitalization groups. The group that underwent 6 months of treatment had a higher percentage of patients with grade III obesity, which partly justifies the longer hospital stay in this group. In a study of patients with obesity grade III who underwent outpatient dietary treatment in Rio de Janeiro, Brazil, most participants were women (76.3%) and adults (average age of 45 years), similar to this study. However, there was a higher prevalence of hypertension (80%) and diabetes (46%) and a lower incidence of drinking habits (37%), sleep apnea (31%), and dyslipidemia (16%) [11], compared to the patient profile of this study. This study is based on a Brazilian, mixed population of predominantly African (50.5%) and European (42.4%) ancestry and fewer Native Americans (5.8%) [12].

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

Both groups revealed significant changes in body composition parameters throughout each period, with a more significant improvement in these variables after 6 months of hospitalization. After 3 months, we observed a significant decrease in weight, BMI, fat mass, body fat percentage, skeletal muscle mass, basal metabolic rate, and WHR. These results indicate a positive response to short-term treatment, suggesting the effectiveness of hospitalization in promoting weight loss and improving body composition. This finding aligns with a study [13] that investigated the effects of short-term multidisciplinary interventions in patients with obesity and demonstrated significant reductions in fat mass, percentage of body fat, and BMI. Skeletal muscle mass and basal metabolic rate also reduced significantly but at a magnitude approximately six times smaller than the fat mass loss (1.6 kg vs. 10.9 kg, respectively), even at six months of treatment. Patients hospitalized for 6 months demonstrated more significant changes in body composition measured by bioimpedance. The magnitude of these changes, especially in the loss of weight (men: 23.6% and women: 20.4%) and fat mass (men: 45.3% and women: 31.3%), suggests that 6 months of hospitalization doubles the reduction in these parameters, with an eight times smaller loss of skeletal muscle mass. In both periods, men exhibited higher percentages of loss in weight, fat mass, percentage of body fat, and WHR, in addition to lesser loss of skeletal muscle mass compared to women. These results corroborate previous findings demonstrating that in short periods of intervention, men experience a more pronounced response in weight reduction with greater preservation of skeletal muscle mass [14-15]. In addition to the differences in bioimpedance parameters previously discussed, the unequal reduction in WHR between men and women was notable in both periods of

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

hospitalization. Men demonstrated a significantly greater reduction (almost double) in WHR. This observation is consistent with previous findings that men have a more pronounced loss of visceral fat and, consequently, a greater reduction in WHR [16-17]. Reduced WHR is associated with cardiovascular benefits and reduced health-related adverse events. Epidemiological studies highlight that a lower WHR reduces the risk of cardiovascular diseases, hypertension, and type 2 diabetes [18]. This association lies in the direct relationship between WHR and visceral fat and, consequently, with insulin resistance and inflammation caused by excess of this fat, factors that play crucial roles in increasing the risk of cardiovascular diseases [19-20]. Despite the different reduction levels in WHR, both sexes improved these measures, suggesting that both men and women experience the benefits in cardiovascular risk resulting from these reductions. Regarding elderly and non-elderly patients, a reduction in weight, BMI, fat mass, percentage of body fat mass, and WHR was observed in both periods. However, nonelderly patients presented better results than elderly patients. A previous study [21] also evaluated the repercussions of treating severe obesity in an inpatient setting in elderly and non-elderly patients. Their results are consistent with ours because although both groups obtained significant results, non-elderly patients exhibited a greater BMI, weight, and waist circumference reduction than the elderly patients. The aging process naturally modifies body composition, which can lead to an increase of 2 to 5% in total fat mass each decade from the age of 40, in addition to a reduction in muscle mass [22]. In this study, the differences in the loss of skeletal muscle mass and reduction in basal metabolic rate were not significant between age groups during the 3month hospitalization. However, during the 6-month hospitalization, elderly patients exhibited greater loss of skeletal muscle mass and, consequently, a greater reduction in

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

basal metabolic rate. This result necessitates the development of strategies and different nutritional protocols for the elderly, which can minimize this loss of muscle mass during a longer period of hospitalization. The relationship between LCD and weight loss and its effects on glucose, lipid, and inflammatory parameters are well documented in the scientific literature (8). In this study, the reduction in blood glucose, insulin, glycated hemoglobin, triglycerides, LDL- and total cholesterol, and CRP was significant in both periods of hospitalization. A small reduction in HDL cholesterol was observed only in the short term and was not maintained after 6 months of hospitalization. These results suggest that inpatient treatment improves the metabolic and inflammatory profile of patients with severe obesity, with implications for reducing cardiovascular risk. Reducing body weight by 5 to 10% improves cardiovascular health, as lipid parameters tend to reduce significantly within this range of weight loss when they are at abnormal levels [23]. The non-significant long-term reduction in HDL cholesterol can be partly explained by the progressive increase in physical activity during hospitalization, associated with improved eating patterns. Therefore, multidisciplinary therapy aimed at lasting changes in lifestyle habits is crucial. Hepatic transaminase GGT levels reduced significantly throughout both periods of hospitalization. GPT levels increased slightly in the first 3 months but decreased at 6 months. Despite not changing significantly in the first 3 months of hospitalization, the GOT level increased slightly at 6 months. This increase may be because of weight loss during hospitalization; it was within the normal range and without clinical implications. Fasting blood glucose, insulin, and glycated hemoglobin levels were significantly reduced

in this study, indicating an improvement in glycemic control and insulin resistance,

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

corroborating previous reports [24-25]. This improvement in glucose parameters demonstrates that this treatment reduces weight and body fat, achieves positive metabolic profile results, and removes the patient from pre-diabetes classification. In both periods of hospitalization, inflammatory marker levels, CRP, and ferritin were also reduced significantly. Reducing weight and body fat mass reduces free fatty acid levels that activate the pro-inflammatory cascade. This increases adiponectin levels, reducing CRP production by reducing the release of interleucin-6 by adipose tissue [24-26]. Elevated ferritin is an important marker of chronic inflammation, cardiovascular risk, and insulin resistance and is associated with inflammation in adipose tissue [27-28]. Therefore, the reduction in ferritin and CRP levels observed in this study reflects an improvement in the inflammatory parameters of patients with severe obesity. A logistic multivariate regression analysis was conducted to understand the factors, measured at admission, associated with the success to reach the median value of fat mass loss percentage at 3 and 6 months of treatment. The model explained approximately 33.5%% and 28.7% of the success to reach such levels of fat mass loss percentage variation after 3 and 6 months of treatment, respectively. Male sex was a significant predictor of the percentage of fat mass loss at both treatment times. Previous reports have indicated greater weight and fat loss in men who underwent interventions to treat obesity [15,29]. A higher percentage of lean mass in men, a greater amount of estrogen produced by women, and differences in insulin resistance between sexes may justify these different responses to treatment [29-30]. Another significant predictor was age; elderly people presented lower chance of reach median values of fat mass loss percentage in both periods of hospitalization, corroborating previous data [21]. Metabolic changes inherent to

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

advancing age, associated with reduced muscle mass and strength [31-32], may explain

this negative association with age. Alcoholism reported on admission was related to a higher chance to reach median percentage of fat mass loss in the first 3 months of hospitalization but not at 6 months. Upon admission, patients stop drinking alcoholic beverages, contributing to a reduction in caloric intake and, consequently, a reduction in fat mass in the short term. Hepatic steatosis was a predictor associated with a higher chance of reach median percentage of fat mass loss at six months of hospitalization. As the liver is one of the main metabolic regulatory organs, hepatic steatosis indicates an altered and compromised metabolism, which seems to respond better to a six months inpatient treatment. Patients with high CPK levels on admission had a higher percentage of fat mass loss in both periods of hospitalization. CPK is an enzyme in muscle cells, with only small amounts released into the bloodstream [33-36]. However, high body fat levels can generate changes in the cell membrane, increasing circulating CPK levels [37]. As the main source of CPK is muscle tissue, the levels of this enzyme can indicate muscle mass, justifying its association with a better response in the loss of body fat. However, more studies are necessary to verify this association. CRP level was a negative predictor of fat mass loss at patient admission in this study. CRP level is an important indicator of subclinical systemic inflammation in individuals with severe obesity [38]. Therefore, the greater difficulty in losing fat mass in patients with higher CRP levels could be explained by a worse inflammatory profile resulting from more dysfunctional adipose tissue. However, more studies are needed to address this question. The zinc level below normal range was associated with a lower chance to reach median level of fat mass reduction at 3 but not at 6 months of treatment. Zinc plays an important role in controlling appetite, has anti-inflammatory action, and is involved in the production of hormones associated with energy metabolism, insulin resistance, and diabetes [39-40]. Therefore, the zinc association reported herein could be explained by its protective effects against insulin resistance, chronic inflammation, and hyperglycemia, leading to higher fat mass loss. Its effect loss at 6 months may be because this micronutrient is supplemented during hospitalization, correcting possible deficiencies and their effects in the long term.

Conclusion

Three and 6 months of inpatient treatment substantially reduced anthropometric measurements in severe obesity, with 6 months yielding better results with approximately 20% reduction in weight, 31% in fat mass, and 6% in the WHR. Furthermore, glucose, lipid, and inflammatory profiles significantly improved in both treatment periods. These results were maintained in elderly and non-elderly patients, men and women, resulting in an improvement in cardiovascular risk and escape from pre-diabetes. This study suggests that VLCD in an inpatient facility with immersive lifestyle changes under multidisciplinary supervision is an alternative and effective intervention for managing severe obesity in the real world.

Acknowledgment

We thank all the professionals of Hospital da Obesidade for their kind support.

References

494

- 1. The GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195
- 498 Countries over 25 Years. N Engl J Med. 2017;377(1):13–27.
- 499 2. Bray GA. Medical Consequences of Obesity. The Journal of Clinical Endocrinology &
- 500 Metabolism. 2004;89(6):2583–9.
- 3. McCafferty BJ, Hill JO, Gunn AJ. Obesity: Scope, Lifestyle Interventions, and Medical
- 502 Management. Techniques in Vascular and Interventional Radiology. 2020;23(1):100653.
- 503 4. Caprio M, Infante M, Moriconi E, Armani A, Fabbri A, Mantovani G, et al. Very-low-
- calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic
- 505 review and consensus statement from the Italian Society of Endocrinology (SIE). J
- 506 Endocrinol Invest. 2019;42(11):1365–86.
- 507 5. Muscogiuri G, Barrea L, Laudisio D, Pugliese G, Salzano C, Savastano S, et al. The
- 508 management of very low-calorie ketogenic diet in obesity outpatient clinic: a practical
- 509 guide. J Transl Med. 2019;17(1):356.
- 510 6. Gupta L, Khandelwal D, Kalra S, Gupta P, Dutta D, Aggarwal S. Ketogenic diet in
- endocrine disorders: Current perspectives. J Postgrad Med. 2017;63(4):242.
- 7. Dalle Grave R, Calugi S, Molinari E, Petroni ML, Bondi M, Compare A, et al. Weight
- Loss Expectations in Obese Patients and Treatment Attrition: An Observational Multicenter
- 514 Study. Obesity Research. 2005;13(11):1961–9.
- 515 8. ABESO. Associação Brasileira para o Estudo da Obesidade e da Síndrome
- 516 Metabólica- ABESO. Diretrizes brasileiras de obesidade. Posicionamento sobre o


- Tratamento Nutricional do Sobrepeso e da Obesidade [Internet]. 2022. Available from:
- 518 https://abeso.org.br/wp-content/uploads/2022/11/posicionamento 2022-alterado-nov-22-
- 519 1.pdf
- 9. Terapia Cognitiva na Prática: Fundamentos Científicos e Técnicos. Artmed; 2021.
- 10. Boff RM, Segalla CD, Feoli AMP, Gustavo AS, Oliveira MS. O modelo transteórico
- 522 para auxiliar adolescentes obesos a modificar estilo de vida. Temas Psicol.
- 523 2018;26(2):1055–67.
- 11. Reis ECD, Passos SRL, Santos MABD, Silva LMLE, Oliveira RDVCD, Camara APS, et
- al. Características de adultos com obesidade grave em tratamento ambulatorial no Rio de
- Janeiro e fatores associados à perda de peso. Cad saúde colet. 2022;30(2):201–14.
- 12. Lima-Costa MF, Rodrigues LC, Barreto ML, Gouveia M, Horta BL, Mambrini J, et al.
- 528 Genomic ancestry and ethnoracial self-classification based on 5,871 community-dwelling
- Brazilians (The Epigen Initiative). Sci Rep. 2015;5(1):9812.
- 530 13. Gasparri C, Perna S, Peroni G, Riva A, Petrangolini G, Faliva MA, et al.
- Multidisciplinary residential program for the treatment of obesity: how body composition
- assessed by DXA and blood chemistry parameters change during hospitalization and
- which variations in body composition occur from discharge up to 1-year follow-up. Eat
- 534 Weight Disord. 2022;27(7):2701–11.
- 14. O'neil PM, Currey HS, Hirsch AA, Riddle FE, Taylor CI, Malcolm RJ, et al. Effects of
- sex of subject and spouse involvement on weight loss in a behavioral treatment program:
- A retrospective investigation. Addictive Behaviors. 1979;4(2):167–77.

- 15. Millward DJ, Truby H, Fox KR, Livingstone MBE, Macdonald IA, Tothill P. Sex
- 539 differences in the composition of weight gain and loss in overweight and obese adults. Br J
- 540 Nutr. 2014;111(5):933-43.
- 16. Kuk JL, Ross R. Influence of sex on total and regional fat loss in overweight and obese
- men and women. Int J Obes. 2009;33(6):629–34.
- 543 17. Wirth A, Steinmetz B. Gender Differences in Changes in Subcutaneous and
- Intra-abdominal Fat during Weight Reduction: An Ultrasound Study. Obesity Research.
- 545 1998;6(6):393–9.
- 18. Megnien J, Denarie N, Cocaul M, Simon A, Levenson J. Predictive value of waist-to-
- 547 hip ratio on cardiovascular risk events. Int J Obes. 1999;23(1):90–7.
- 19. Welborn TA, Dhaliwal SS, Bennett SA. Waist-hip ratio is the dominant risk factor
- 549 predicting cardiovascular death in Australia. Medical Journal of Australia.
- 550 2003;179(11):580–5.
- 20. Czernichow S, Kengne AP, Huxley RR, Batty GD, De Galan B, Grobbee D, et al.
- Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular
- 553 disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE.
- European Journal of Cardiovascular Prevention & Rehabilitation. 2011;18(2):312–9.
- 21. Budui S, Bigolin F, Giordano F, Leoni S, Berteotti M, Sartori E, et al. Effects of an
- Intensive Inpatient Rehabilitation Program in Elderly Patients with Obesity. Obes Facts.
- 557 2019;12(2):199–210.
- 558 22. Tchernof A, Després JP. Pathophysiology of Human Visceral Obesity: An Update.
- 559 Physiological Reviews. 2013;93(1):359–404.


- 23. Dattilo A, Kris-Etherton P. Effects of weight reduction on blood lipids and lipoproteins:
- a meta-analysis. The American Journal of Clinical Nutrition. 1992;56(2):320–8.
- 24. Abbas H, Perna S, Shah A, Gasparri C, Rondanelli M. Efficacy and Safety of a Long-
- Term Multidisciplinary Weight Loss Intervention under Hospitalization in Aging Patients
- with Obesity: An Open Label Study. Nutrients. 2022;14(16):3416.
- 25. Von Bibra H, Wulf G, St John Sutton M, Pfützner A, Schuster T, Heilmeyer P. Low-
- 566 carbohydrate/high-protein diet improves diastolic cardiac function and the metabolic
- syndrome in overweight-obese patients with type 2 diabetes. IJC Metabolic & Endocrine.
- 568 2014;2:11–8.
- 26. Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial Dysfunction in Obesity-Induced
- 570 Inflammation: Molecular Mechanisms and Clinical Implications. Biomolecules.
- 571 2020;10(2):291.
- 572 27. Ryan BJ, Van Pelt DW, Guth LM, Ludzki AC, Gioscia-Ryan RA, Ahn C, et al. Plasma
- ferritin concentration is positively associated with *in vivo* fatty acid mobilization and insulin
- resistance in obese women. Experimental Physiology. 2018;103(11):1443–7.
- 575 28. Justi A, Tatsch P, Sigueira LO. Ferritina: biomarcador de doencas cardiovasculares
- 576 em pacientes diabéticos. ABCS Health Sci [Internet]. 2019 [citado 10 de janeiro de
- 577 2024];44(1). Available from: https://www.portalnepas.org.br/abcshs/article/view/1145
- 578 29. Williams RL, Wood LG, Collins CE, Callister R. Effectiveness of weight loss
- interventions is there a difference between men and women: a systematic review.
- 580 Obesity Reviews. 2015;16(2):171–86.

- 30. Wu BN, O'Sullivan AJ. Sex Differences in Energy Metabolism Need to Be Considered
- with Lifestyle Modifications in Humans. Journal of Nutrition and Metabolism. 2011;2011:1–
- 583 6.
- 31. S. Fry C, B. Rasmussen B. Skeletal Muscle Protein Balance and Metabolism in the
- 585 Elderly. CAS. 2011;4(3):260–8.
- 32. Rezuş E, Burlui A, Cardoneanu A, Rezuş C, Codreanu C, Pârvu M, et al. Inactivity and
- 587 Skeletal Muscle Metabolism: A Vicious Cycle in Old Age. IJMS. 2020;21(2):592.
- 33. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects
- of creatine in the central nervous system. Brain Research Bulletin. 2008;76(4):329–43.
- 34. Saks VA, Rosenshtraukh LV, Smirnov VN, Chazov El. Role of creatine phosphokinase
- in cellular function and metabolism. Can J Physiol Pharmacol. 1978;56(5):691–706.
- 35. Levitsky DO, Levchenko TS, Saks VA, Sharov VG, Smirnov VN. The Role of Creatine
- 593 Phosphokinase in Supplying Energy for the Calcium Pump System of Heart Sarcoplasmic
- Reticulum. Membrane Biochemistry. 1978;2(1):81–96.
- 595 36. Moghadam-Kia S, Oddis CV, Aggarwal R. Approach to asymptomatic creatine kinase
- 596 elevation. CCJM. 2016;83(1):37–42.
- 37. Kim J, Yoon JH. Does Obesity Affect the Severity of Exercise-Induced Muscle Injury?
- Journal of Obesity & Metabolic Syndrome. 2021;30(2):132–40.
- 599 38. Ion RM, Sibianu M, Hutanu A, Beresescu FG, Sala DT, Flavius M, et al. A
- 600 Comprehensive Summary of the Current Understanding of the Relationship between
- Severe Obesity, Metabolic Syndrome, and Inflammatory Status. JCM. 2023;12(11):3818.


39. Shay NF, Mangian HF. Neurobiology of Zinc-Influenced Eating Behavior. The Journal 602 of Nutrition. 2000;130(5):1493S-1499S. 603 40. Skalny AV, Aschner M, Tinkov AA. Zinc. Advances in Food and Nutrition Research. 604 2021; 96:251-310. Available 605 from: https://linkinghub.elsevier.com/retrieve/pii/S1043452621000036 606 607 608 609




Figure



Figure



Figure



Figure